Northern Trust’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$84.4M Buy
1,537,059
+94,480
+7% +$3.87M 0.01% 894
2026
Q1
$47.9M Buy
1,442,579
+23,060
+2% +$687K 0.01% 1121
2025
Q4
$42.3M Sell
1,419,519
-82,214
-5% -$2.69M 0.01% 1214
2025
Q3
$54.3M Sell
1,501,733
-33,990
-2% -$1.12M 0.01% 1083
2025
Q2
$55.3M Buy
1,535,723
+6,316
+0.4% +$235K 0.01% 1043
2025
Q1
$60.3M Sell
1,529,407
-3,522
-0.2% -$119K 0.01% 983
2024
Q4
$46.1M Buy
1,532,929
+120,785
+9% +$3.47M 0.01% 1177
2024
Q3
$33M Buy
1,412,144
+135,827
+11% +$2.97M 0.01% 1304
2024
Q2
$22.7M Sell
1,276,317
-24,071
-2% -$384K ﹤0.01% 1474
2024
Q1
$19.8M Sell
1,300,388
-50,547
-4% -$805K ﹤0.01% 1601
2023
Q4
$23.1M Sell
1,350,935
-7,063
-0.5% -$82.1K ﹤0.01% 1513
2023
Q3
$11.4M Buy
1,357,998
+9,198
+0.7% +$128K ﹤0.01% 1909
2023
Q2
$33.5M Buy
1,348,800
+47,033
+4% +$1.21M 0.01% 1228
2023
Q1
$19.6M Buy
1,301,767
+30,969
+2% +$470K ﹤0.01% 1563
2022
Q4
$15M Buy
1,270,798
+16,005
+1% +$116K ﹤0.01% 1732
2022
Q3
$7.43M Buy
1,254,793
+9,904
+0.8% +$65K ﹤0.01% 2195
2022
Q2
$5.29M Sell
1,244,889
-7,830
-0.6% -$48.9K ﹤0.01% 2475
2022
Q1
$11.9M Sell
1,252,719
-56,051
-4% -$649K ﹤0.01% 2038
2021
Q4
$24.9M Sell
1,308,770
-5,650
-0.4% -$147K ﹤0.01% 1622
2021
Q3
$43.7M Sell
1,314,420
-49,777
-4% -$1.54M 0.01% 1185
2021
Q2
$52.9M Buy
1,364,197
+29,604
+2% +$1.16M 0.01% 1093
2021
Q1
$64.3M Sell
1,334,593
-19,965
-1% -$959K 0.01% 922
2020
Q4
$70.5M Buy
1,354,558
+9,379
+0.7% +$317K 0.01% 839
2020
Q3
$36M Buy
1,345,179
+76,923
+6% +$1.77M 0.01% 1144
2020
Q2
$24.7M Buy
1,268,256
+154,157
+14% +$2.48M 0.01% 1439
2020
Q1
$11M Buy
1,114,099
+28,794
+3% +$364K ﹤0.01% 1816
2019
Q4
$12M Buy
1,085,305
+25,195
+2% +$192K ﹤0.01% 2061
2019
Q3
$5.95M Buy
1,060,110
+216,967
+26% +$1.51M ﹤0.01% 2456
2019
Q2
$7.29M Buy
843,143
+33,200
+4% +$251K ﹤0.01% 2343
2019
Q1
$6.51M Buy
809,943
+8,383
+1% +$45.3K ﹤0.01% 2403
2018
Q4
$3.29M Sell
801,560
-20,879
-3% -$104K ﹤0.01% 2759
2018
Q3
$4.61M Buy
822,439
+70,714
+9% +$808K ﹤0.01% 2730
2018
Q2
$9.88M Buy
751,725
+121,424
+19% +$1.67M ﹤0.01% 2276
2018
Q1
$8.95M Buy
630,301
+12,517
+2% +$160K ﹤0.01% 2240
2017
Q4
$5.07M Buy
617,784
+20,886
+3% +$182K ﹤0.01% 2599
2017
Q3
$7.07M Sell
596,898
-1,728
-0.3% -$19.7K ﹤0.01% 2413
2017
Q2
$6.02M Buy
598,626
+134,463
+29% +$1.51M ﹤0.01% 2507
2017
Q1
$5.41M Buy
464,163
+5,953
+1% +$42.7K ﹤0.01% 2513
2016
Q4
$2.13M Buy
458,210
+3,489
+0.8% +$20.5K ﹤0.01% 3054
2016
Q3
$3.52M Sell
454,721
-5,567
-1% -$35.8K ﹤0.01% 2760
2016
Q2
$2.79M Buy
460,288
+13,194
+3% +$107K ﹤0.01% 2849
2016
Q1
$3.81M Buy
447,094
+5,179
+1% +$45.3K ﹤0.01% 2583
2015
Q4
$5.27M Buy
441,915
+15,552
+4% +$196K ﹤0.01% 2437
2015
Q3
$4.3M Buy
426,363
+65,723
+18% +$979K ﹤0.01% 2536
2015
Q2
$5.98M Buy
360,640
+53,437
+17% +$846K ﹤0.01% 2413
2015
Q1
$4.76M Buy
307,203
+6,712
+2% +$102K ﹤0.01% 2537
2014
Q4
$4.76M Buy
300,491
+44,482
+17% +$579K ﹤0.01% 2537
2014
Q3
$2.73M Buy
256,009
+32,717
+15% +$303K ﹤0.01% 2893
2014
Q2
$2.1M Buy
223,292
+4,864
+2% +$31.1K ﹤0.01% 3071
2014
Q1
$1.51M Buy
218,428
+5,102
+2% +$30.2K ﹤0.01% 3264
2013
Q4
$832K Buy
213,326
+10,517
+5% +$42.5K ﹤0.01% 3430
2013
Q3
$1.02M Buy
202,809
+133,775
+194% +$818K ﹤0.01% 3322
2013
Q2
$441K Buy
+69,034
New +$442K ﹤0.01% 3484

Other funds holding TGTX

Northern Trust's TGTX Position: Q2 2026 in Review

Northern Trust increased its TG Therapeutics (TGTX) stake by 6.5% in Q2 2026, buying an estimated $3.87M and bringing the position to 1,537,059 shares worth $84.4M. The position accounts for 0.01% of the portfolio, ranked #894.

Northern Trust first reported a position in TGTX in Q2 2013 and has held it in 53 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Northern Trust held 1,537,059 shares of TG Therapeutics worth $84.4M as of Q2 2026.
  • Northern Trust bought 94,480 TG Therapeutics shares in Q2 2026, an estimated $3.87M.
  • TG Therapeutics made up 0.01% of Northern Trust's portfolio in Q2 2026, its #894 holding.
  • Northern Trust first reported a position in TG Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.